AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Compounds in Late-Stage Clinical Development with by Year
Compounds in Late-Stage Clinical Development with Novel Mechanism of Action (%) (%)
AbbVie Compounds in Late-Stage Clinical Development with: 80.0% in FY2025, up 24.0 pts from a year earlier.
Latest, FY2025
80.0%
Period ended Dec 31, 2025
Change on a year earlier
+24.0 pts
56.0% in FY2024
History
5 years
Since FY2021
Sources
2
Documents cited below
Where the FY2025 figure comes from
“Percentage of Compounds in FDA Breakthrough Therapy Employees in R&D Positions12 Late-Stage Clinical Development Designations Granted by Year with Novel Mechanism of Action Business Sustainability 80% 1 1 1 ~15,000 56% 50% 2023 2024 2025 2023 2024 2025 2023 2024* 2025”
Source: AbbVie 2025 ESG Action Report ↗
Reported in AbbVie ESG Action Reports.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Compounds in Late-Stage Clinical Development with Novel Mechanism of Action (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 80.0% | +24.0 pts | AbbVie 2025 ESG Action Report ↗ |
| FY2024 | Dec 31, 2024 | 56.0% | +6.0 pts | AbbVie 2025 ESG Action Report ↗ |
| FY2023 | Dec 31, 2023 | 50.0% | -10.0 pts | AbbVie 2025 ESG Action Report ↗ |
| FY2022 | Dec 31, 2022 | 60.0% | -20.0 pts | AbbVie 2023 ESG Action Report ↗ |
| FY2021 | Dec 31, 2021 | 80.0% | – | AbbVie 2023 ESG Action Report ↗ |
Cite this data
StockData. (2026). AbbVie Compounds in Late-Stage Clinical Development with (%), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rd-novel-moa-pct
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.